XIENCE Nano Coronary Stent System from Abbott Receives FDA Approval

Abbott declared that Food and Drug Administration has approved its XIENCE nano Everolimus Eluting Coronary Stent System, which is a new treatment system for patients suffering from coronary heart disease.

The new system is capable of treating blocks in vessels with diameter as small as 2.25 mm. Marco Costa, professor of medicine and the director of many research institutes, explained that treating vessels of small diameter is a challenging proposition, which XIENCE, the nano stent is capable of treating successfully.

The approval was backed by the results from the SPIRIT Small Vessel clinical trial, where XIENCE nano showed a very low late loss of 0.20 mm and target lesion failure (TLF) of 8.1%.TLF is a vital measurement that indicates the risk of various heart diseases. In most cases after the placement of the stent, problems such as tissue re-growth and restenosis occur. But XIENCE nano eliminates the problem of tissue re-growth through the use of cobalt chromium as the stent material and the everolimus drug coating. The XIENCE stents are now available in the U.S with the diameter ranging from 2.25 to 4 mm. The size of the struts in the XIENCE nano is as small as 0.0032”.